Table 2.
Tumor response, recurrence of malignancy, and adverse events in patients treated with Stereotactic Body Radiation Therapy for nonresectable liver tumors.
| HCC | IHC | LM | Total | |
|---|---|---|---|---|
| Subjects | 6 | 3 | 8 | 17 |
| Mean of Follow Up (months) | 10.0 | 5.9 | 6.9 | 7.8 |
| Tumor Response | ||||
| RECIST | Complete (0) | Complete (0) | Complete (0) | Complete (0) |
| Partial (5) | Partial (2) | Partial (7) | Partial (4) | |
| Stable (1) | Stable (0) | Stable (1) | Stable (2) | |
| Progress (0) | Progress (1) | Progress (0) | Progress (1) | |
| Partial Tumor | Grade I (0) | Grade I (2) | Grade I (0) | Grade I (2) |
| Response Grade | Grade II (3) | Grade II (0) | Grade II (2) | Grade II (5) |
| Grade III (3) | Grade III (1) | Grade III (6) | Grade III (10) | |
| Tumor Recurrence | ||||
| Grade 0 (4) | Grade 0 (1) | Grade 0 (4) | Grade 0 (9) | |
| Grade 1a (0) | Grade 1a (0) | Grade 1a (0) | Grade 1a (0) | |
| Grade 1b (0) | Grade 1b (1) | Grade 1b (0) | Grade 1b (1) | |
| Grade 2 (1) | Grade 2 (1) | Grade 2 (2) | Grade 2 (4) | |
| Grade 3 (1) | Grade 3 (0) | Grade 3 (0) | Grade 3 (1) | |
| Grade 4 (0) | Grade 4 (0) | Grade 4 (2) | Grade 4 (2) | |
| Adverse events | ||||
| From SBRT | 0 | 0 | 0 | 0 |
| From markers | 0 | 0 | 2 | 2 |
| From surgery | 0 | 0 | 0 | 0 |
| # Patients Expired | 2 | 3 | 3 | 8 |